Mutations in the lamin A/C gene (LMNA) encoding A-type nuclear lamins cause dilated cardiomyopathy with variable muscular dystrophy. These mutations enhance mitogen-activated protein kinase signaling in the heart and pharmacological inhibition of extracellular signal-regulated kinase (ERK) 1 and 2 improves cardiac function in Lmna H222P/H222P mice. In the current study, we crossed mice lacking ERK1 to Lmna H222P/H222P mice and examined cardiac performance and survival. Male Lmna 
INTRODUCTION
Mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins of the nuclear envelope expressed in most differentiated somatic cells, cause a diverse range of diseases often called laminopathies (1, 2) . Laminopathies selectively affect different tissues and organ systems, leading to striated muscle disease, partial lipodystrophy, peripheral neuropathy and multisystem disorders such as Hutchinson -Gilford progeria syndrome that have features of accelerated aging. Of the laminopathies, the most prevalent affect striated muscle and manifest as cardiomyopathy with or without different types of skeletal muscular dystrophy (3) .
The striated muscle condition caused by LMNA mutations was originally defined as distinct, clinical disorders based on the collections of patients originally studied and included autosomal Emery-Dreifuss muscular dystrophy (4), isolated cardiomyopathy and conduction defects with minimal skeletal muscle involvement (5) and limb-girdle muscular dystrophy 1B (6) . It is now apparent that any of these classical clinical phenotypes, as well as overlapping phenotypes, can be caused by LMNA mutations, even by the same mutation within the same family (7, 8) . The common feature is cardiomyopathy characterized by left ventricular dilatation and systolic dysfunction of one or both ventricles. Affected subjects also typically have early heart block and a course complicated by other arrhythmias. While sudden death from arrhythmias may be prevented by implantation of a pacemaker and/or defibrillator, heart failure occurs in 64% of patients by the age 50 years, eventually becoming resistant to symptomatic treatment and necessitating cardiac transplantation (9) .
We have discovered an abnormal activation of the extracellular signal-regulated kinase (ERK) 1/2 branch of the mitogenactivated protein kinase signaling cascade in hearts of knock-in mice with a Lmna H222P mutation (10) . The orthologous mutation causes Emery -Dreifuss muscular dystrophy in humans and homozygous Lmna H222P knock-in mice develop dilated cardiomyopathy and skeletal muscle disease mimicking affected human subjects (11) . We have further demonstrated that small molecule inhibitors of mitogen-activated protein/ extracellular signal-regulated kinase (MEK) 1/2, the enzymes that phosphorylate and activate ERK1/2, have beneficial effects on heart function as well as survival in Lmna H222P/ H222P mice (12 -14) .
The discovery that treatment with MEK1/2 inhibitors ameliorates cardiomyopathy in Lmna H222P/H222P mice suggests that ERK1/2 hyperactivation plays an underlying role in the pathogenesis of cardiomyopathy caused by LMNA mutations. However, unknown off-target effects could potentially confuscate the interpretation of results obtained with small molecule enzymes inhibitors. Results obtained using pharmacological inhibitors could further be influenced by factors such as the time of treatment initiation, duration of treatment and pharmacokinetic variables such as alterations in drug distribution in animals with heart failure. MEK1/2 inhibitors are also not selective in terms of blocking activation of the ERK1 and ERK2 isoenzymes. Here, we examine the role of the ERK1 in the development of cardiomyopathy caused by LMNA mutation by depleting this isoenzyme from Lmna H222P/H222 mice. The results obtained using a genetic approach, independent of pharmacological inhibitors, confirm the role of ERK1/2 in pathogenesis. They also reveal interplay between ERK1 and ERK2 in maintaining a combined pathologic activity in heart.
RESULTS

Generation of Lmna
H222P/H222P mice lacking ERK1
To definitively prove that ERK1/2 plays a central role in the pathogenesis of cardiomyopathy caused by LMNA mutations, we crossed mice lacking ERK1 to Lmna H222P/H222P mice. As Erk2 2/2 mice die during embryonic development (15,16), we focused on ERK1, which could be completely depleted genetically. Erk1 2/2 mice are viable and fertile, and only thymocyte proliferation and maturation has been reported to be abnormal (17) . Erk1 2/2 null mice have normal heart structure and function (18) .
We crossed male and female Lmna H222P/+ /Erk1 /Erk1 +/+ mice (Fig. 1B) . Erk1 mRNA was also absent from heart tissue of Lmna +/+ /Erk1
and Lmna
H222P/H222P
/Erk1 2/2 mice analyzed by reverse transcription followed by real-time quantitative polymerase chain reaction (Fig. 1C) . (Fig. 2B ), confirming that the lack of ERK1 was not apparently detrimental to the heart (18) . However, at 16 weeks of age, Lmna H222P/H222P / Erk1 2/2 mice had a significant 12% smaller mean LVESD and a significant increase of 20% in FS compared with Lmna H222P/H222P /Erk1 +/+ mice (Fig. 2B) . We also examined the expression of genes encoding natriuretic peptide precursors, which are upregulated by left ventricular dilatation (19) . Compared with Lmna H222P/H222P /Erk1 +/+ mice, hearts from (Fig. 2D) . Hence, depletion of ERK1 prevented or delayed the development of significant left ventricular dilatation and dysfunction in Lmna H222P/H222P mice.
Effect of genetic deletion of Erk1 on survival of Lmna H222P/H222P mice Lmna H222P/H222P mice have a significantly shorter lifespan than wild-type mice with all of the male mice dying between 16 and 40 weeks of age (11, 20) . We have previously shown that treatment with the MEK1/2 inhibitor selumetinib, which blocks activation of both ERK1 and ERK2, prolonged the median survival of Lmna H222P/H222P mice by .10% (14) . We therefore examined if the lack of ERK1 altered survival (the time to death or significant distress requiring euthanasia) in Lmna H222P/H222P mice. Compared with Lmna H222P/H222P / Erk1 +/+ mice, Lmna H222P/H222P /Erk1 2/2 mice had a significantly prolonged mean but not median survival (Fig. 3) (Fig. 5A ). In hearts from Lmna +/+ / Erk1 2/2 mice lacking ERK1 without the Lmna H222P mutation, there was no significant change in ERK2 activity between 16 and 20 weeks of age (Fig. 5B) . In hearts from Lmna H222P/ H222P /Erk1 2/2 mice, however, there was a significant increase in ERK2 activity at 20 weeks compared with 16 weeks of age ( Fig. 5A and B) . 
/Erk1
2/2 mice suggested that it 'pathologically compensates' for the loss of ERK1 in these animals. To test this hypothesis, we treated 16-week-old Lmna H222P/H222P /Erk1 2/2 mice with selumetinib, which inhibits MEK1/2, the kinase that phosphorylates ERK2. As shown by immunoblotting of proteins in tissue homogenates (Fig. 6A) , hearts of 20-week-old mice treated with selumetinib 
had significantly reduced levels of phosphorylated ERK2 compared with those in hearts from mice treated with dimethyl sulfoxide (DMSO) as a placebo (Fig. 6B ).
We performed transthoracic echocardiograms on Lmna H222P/ H222P /Erk1 2/2 treated with selumetinib for placebo from 16 to 20 weeks of age (Fig. 7A) . From the echocardiograms, we calculated mean heart rate, LVEDD, LVESD and FS (Table 3) . LVEDD and LVESD were both significantly smaller and FS significantly greater in Lmna H222P/H222P /Erk1 2/2 mice treated with selumetinib compared with placebo-treated mice (Fig. 7B) . Hearts from the selumetinib-treated Lmna H222P/H222P /Erk1
mice also had significantly reduced expression of Nppa (Fig. 7C) and Nppb (Fig. 7D ) compared with placebo-treated controls. These results showed that inhibition of ERK2 in hearts of Lmna H222P/H222P lacking ERK1 improves left ventricular performance, at least in part reversing the effects of the observed increase in ERK2 activity that occurs after 16 weeks of age in these animals.
Enhanced p38a and c-Jun NH2-terminal kinase activity in hearts of 20-week-old Lmna H222P/H222P mice lacking ERK1
We have previously shown that in addition to ERK1/2 the mitogen-activated protein kinases p38a and c-Jun NH2-terminal kinase (JNK) have increased activities in hearts of Lmna H222P/H222P mice (10,13,21). We therefore examined their activities in hearts from Lmna H222P/H222P /Erk1 2/2 mice at 16 and 20 weeks of age. We performed immunoblotting to detect phosphorylated (activated) and total p38a and phosphorylated (activated) and total JNK in hearts of Lmna +/+ /Erk1
and Lmna H222P/H222P /Erk1 2/2 mice (Fig. 8A) . In hearts of Lmna +/+ /Erk1 2/2 mice lacking ERK1 without the Lmna H222P mutation, there was no significant change p38a (Fig. 8B) or JNK (Fig. 8C) activities between 16 and 20 weeks of age. In hearts from Lmna H222P/H222P
2/2 mice, however, there were significant increases in both p38a (Fig. 8B) and JNK (Fig. 8C ) activities at 20 weeks compared with 16 weeks of age.
DISCUSSION
Abnormally increased activation of mitogen-activated protein kinases, including ERK1/2, has been implicated in the pathogenesis of cardiomyopathy caused by LMNA mutations (10) . We have now shown that germline deletion of Erk1 from mice with the cardiomyopathy-causing Lmna (11) . Genetic deletion of Erk1 leads to a significant improvement in FS of 30%.
The improvement in heart function in Lmna H222P/H222P mice lacking Erk1 disappeared at 20 weeks of age concurrent with a greater than 2-fold increase in ERK2 activation in the Lmna H222P/H222P mice lacking ERK1. Blocking cardiac ERK2 activity by treatment with the MEK1/2 inhibitor selumetinib leads to a significant improvement in FS at 20 weeks, strongly suggesting that the increased ERK2 activity after 16 weeks of age leads to the deterioration in heart function in the Lmna H222P/H222P mice lacking Erk1. In embryonic fibroblasts and thymocytes from Erk1 2/2 mice, the amount of ERK2 is unchanged but there is a more sustained activation than in wildtype cells after stimulation with extracellular factors (17) . Brains from Erk1 2/2 mice similarly have no change in the amount of ERK2 but neurons in primary culture have enhanced phosphorylation of ERK2 after stimulating glutamate receptors or inducing membrane depolarization with potassium chloride (22) . Removal of ERK1 from cultured fibroblasts by RNA interference also increases activation of ERK2 (23, 24) . In hearts of Lmna H222P/H222P mice lacking Erk1, however, the increased 'pathological' activation of ERK2 did not occur until after 16 weeks of age. Hence, germline depletion of Erk1 had a transient beneficial effect on cardiomyopathy in these animals. This enhanced ERK2 activity that occurs at a later age in hearts of mice lacking Erk1 has not been previously reported. In a study of a mouse model of Noonan syndrome in which the animals develop hypertrophic cardiomyopathy, depletion of ERK1 by crossing to Erk1 2/2 mice resulted in improved cardiac function at 15 weeks of age; however, heart function at later ages was not reported (25) . Studies examining the role of ERK1/2 in protecting myocardium from ischemic injury and in cardiac hypertrophy also did not look at ERK2 activity in Erk1 2/2 mice older than 10 weeks (18,26) .
The precise roles of ERK1/2 in normal physiology and pathology are not entirely clear despite considerable research. Enhanced activation of ERK1/2 occurs in dilated hearts of human subjects with late-stage cardiac failure resulting from several different causes (27, 28) . In contrast, hearts of male Lmna H222P/H222P mice have detectable increased activity of these kinases as early as 4 weeks of age, when cardiac structure and function are normal and mice have no evidence of cardiomyopathy (10, 29) . Primary activation of ERK1/2 signaling has most often been associated with a hypertrophic response. Transgenic expression in mice of the ERK1/2 kinase MEK1 has been reported to lead to compensated hypertrophy without signs of cardiomyopathy or lethality up to 12 months of age (30) . Expression in transgenic mice of Ras, which activates MEK1/2, has been reported to cause cardiac hypertrophy and selective diastolic dysfunction (31) . However, genetic deletion of both ERK1 and ERK2 from mouse hearts does not block the cardiac hypertrophic response but does affect the balance between eccentric and concentric growth (32) . In humans, activation mutations affecting components of the Ras-Raf-MEK-ERK pathway that activate the ERK1/2 signaling cause several syndromatic disorders that often have cardiac hypertrophy as a feature (33) (34) (35) (36) (37) (38) (39) . However, Lmna H222P/H222P mice and most human subjects with cardiomyopathy caused by LMNA mutations have left ventricular dilation without a preceding hypertrophic phase (9, 11) . Therefore, the pathogenic response of the heart to early, enhanced ERK1/2 activity is complex, likely resulting in hypertrophic or primary dilated cardiomyopathy depending upon factors such as the degree of activation, time of onset of abnormal activity and concurrent activities of other pathways. In addition to enhanced ERK1/2 signaling, hearts from Lmna H222P/H222P mice also have enhanced activity of the mitogen-activated protein kinases JNK and p38a early in the course of disease (10,13,21), which we observed in the hearts of these mice mice have increased activity of this kinase compared with Lmna +/+ mice at earlier ages (21) . This result suggests some type of 'cross talk' between ERK1/2 and p38a signaling. There is also enhanced AKT-mTOR signaling prior to the onset of cardiomyopathy in hearts of Lmna H222P/H222P mice, which is reduced by blocking ERK1/2 activity (40), suggesting 'cross talk' between ERK1/2 and this pathway as well in hearts of Lmna H222P/H222P mice. Future experiments using inhibitors of p38a, JNK and mTOR in Lmna H222P/H222P /Erk1 2/2 mice and examining their effects on heart function could help elucidate the separate or overlapping contributions of these different signaling pathways to heart pathology caused by Lmna mutation.
While we have previously shown benefits of MEK1/2 inhibitors in Lmna H222P/H222P mice (12) (13) (14) , the present experimental results using a purely genetic approach definitively confirm ERK1 as a molecular target for therapeutic interventions. While treatment with MEK1/2 inhibitors provide some survival benefit to Lmna H222P/H222P mice (14) , they still have a shortened lifespan compared with wild-type animals. Early death of Lmna H222P/H222P mice even after blocking ERK1/2 activity may be secondary to involvement of the diaphragm, which does not occur in human subjects with LMNA mutations. The early death may also be due to cardiac arrhythmias, which in human could be prevented by implantation of a pacemaker and defibrillator. In addition, attenuating other contributing pathogenic mechanisms in addition to ERK1/2 signaling may be required to obtain a robust therapeutic response. Nonetheless, the fact that inhibition of ERK1/2 signaling has clear beneficial effects on cardiac function and confers survival benefits in Lmna H222P/H222P mice provide strong support for a clinical trial of a MEK1/2 in human subjects. Only this will determine if such treatment can slow the progression of heart damage, improve cardiac function and delay the development of severe heart failure in patients with cardiomyopathy caused by LMNA mutations.
MATERIALS AND METHODS
Mice
Lmna
H222P/H222P mice (11) 2/2 mice. These mice and offspring from interbreeding of siblings of each of these genotypes were used for the experiments reported in this paper. Genotyping was performed by PCR using genomic DNA isolated from tail clippings. Mice were fed a chow diet and housed in a disease-free barrier facility with 12/12 h light/dark cycles. The Institutional Animal Care and Use Committee at Columbia University Medical Center approved the use of animals and all experimental protocols.
Protein extraction and immunoblotting
Hearts were excised from sacrificed mice and tissue homogenized in extraction buffer as described previously (10, 12 
Reverse transcription and quantitative polymerase chain reaction
Total RNA was extracted from heart tissue using the RNeasy isolation kit (Qiagen) as described previously (12, 13 ′ -ggatgcagggatgatgttc-3 ′ ). Quantitative polymerase chain reaction reactions were carried out on an ABI 7300 RealTime PCR System (Applied Biosystems) using HotStart-IT SYBR green qPCR Master Mix (Affymetrix). Relative levels of mRNA expression were calculated using the DDC T method (41) . Individual expression values were normalized by comparison with Gapdh mRNA.
Thansthoracic echocardiography
Mice were anesthetized with isoflurane/oxygen (1.5%) and body temperature was maintained at 378C. Transthoracic 2D and M-mode echocardiography was performed using a Vevo 770 imaging system (Visualsonics) equipped with a 30-MHz linear transducer applied to the chest wall. Measurements of LVESD, LVEDD and FS were averaged from at least three separate cardiac cycles for the number of animals indicated in each experiment. The echocardiography was blinded to the genotype or treatment of the mice.
Mouse survival analysis
End points for survival analysis were death or significant distress requiring euthanasia. Significant distress included (i) difficulty
with normal ambulation, (ii) failure to eat or drink, (iii) loss of .20% body mass, (iv) depression, (v) rough or unkempt hair coat and (vi) significant respiratory distress. These were confirmed by consulting with veterinarians at the Institute of Comparative Medicine at Columbia University Medical Center. Euthanasia was performed in a CO 2 chamber followed by cervical dislocation, according to the protocol of the Institute of Comparative Medicine. Euthanasia was confirmed by checking for lack of response to limb and tail pinch.
Selumetinib treatment
Selumetinib (Selleck Chemicals) was dissolved in DMSO (Sigma) at a concentration of 0.5 mg/ml. The placebo control consisted of the same volume of DMSO. Selumetinib was administered at a dose of 1 mg/kg/day by intraperitoneal injection using a 27 G 5/8 syringe starting when mice were 16 weeks of age and continuing until 20 weeks of age.
Statistical analysis
Statistical significance comparison between two groups was determined using the Student t-test. For comparisons between more than two groups, significance was determined using Welch ANOVA and Tukey adjustment for post hoc multiple comparisons. Survival curves were generated using the Kaplan -Meier estimator method (42) . Survival data for Lmna H222P/H222P /Erk1 +/+ and Lmna
H222P/H222P
/Erk1 2/2 mice passed D'Agostino and Pearson omnibus normality test (43) and Student t-test was then used to determine statistical significance between mean survivals of these two groups. Statistical analyses were performed using GraphPad (Prism Software).
